194 related articles for article (PubMed ID: 24430597)
1. Neuroendocrine tumors of the pancreas: current concepts and controversies.
Reid MD; Balci S; Saka B; Adsay NV
Endocr Pathol; 2014 Mar; 25(1):65-79. PubMed ID: 24430597
[TBL] [Abstract][Full Text] [Related]
2. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
[TBL] [Abstract][Full Text] [Related]
3. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.
Lee L; Ito T; Jensen RT
Expert Rev Anticancer Ther; 2018 Sep; 18(9):837-860. PubMed ID: 29973077
[TBL] [Abstract][Full Text] [Related]
4. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract][Full Text] [Related]
5. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
[TBL] [Abstract][Full Text] [Related]
6. Surgical management of primary pancreatic neuroendocrine tumors.
Johnston ME; Carter MM; Wilson GC; Ahmad SA; Patel SH
J Gastrointest Oncol; 2020 Jun; 11(3):578-589. PubMed ID: 32655937
[TBL] [Abstract][Full Text] [Related]
7. Dual-color immunocytochemistry (Ki-67 with LCA) for precise grading of pancreatic neuroendocrine tumors with applicability to small biopsies and cell blocks.
Mejías-Badillo L; Jeanty J; Khalid K; Bhalla A; Salem N; Thomas S; Shidham VB
Cytojournal; 2020; 17():6. PubMed ID: 32395150
[TBL] [Abstract][Full Text] [Related]
8. Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Marchese U; Gaillard M; Pellat A; Tzedakis S; Abou Ali E; Dohan A; Barat M; Soyer P; Fuks D; Coriat R
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053593
[TBL] [Abstract][Full Text] [Related]
9. Unravelling actionable biology using transcriptomic data to integrate mitotic index and Ki-67 in the management of lung neuroendocrine tumors.
Manem VSK; Sazonova O; Gagné A; Orain M; Khoshkrood-Mansoori B; Gaudreault N; Bossé Y; Joubert P
Oncotarget; 2021 Feb; 12(3):209-220. PubMed ID: 33613848
[TBL] [Abstract][Full Text] [Related]
10. Malignant potential of neuroendocrine microtumor of the pancreas harboring high-grade transformation: lesson learned from a patient with von Hippel-Lindau syndrome.
Lee J; Lee KJ; Hwang DW; Hong SM
J Pathol Transl Med; 2024 Mar; 58(2):91-97. PubMed ID: 38499005
[TBL] [Abstract][Full Text] [Related]
11. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
12. Update on pancreatic neuroendocrine tumors.
McKenna LR; Edil BH
Gland Surg; 2014 Nov; 3(4):258-75. PubMed ID: 25493258
[TBL] [Abstract][Full Text] [Related]
13. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
Klimstra DS; Beltran H; Lilenbaum R; Bergsland E
Am Soc Clin Oncol Educ Book; 2015; ():92-103. PubMed ID: 25993147
[TBL] [Abstract][Full Text] [Related]
14. Practical management and treatment of pancreatic neuroendocrine tumors.
Kondo NI; Ikeda Y
Gland Surg; 2014 Nov; 3(4):276-83. PubMed ID: 25493259
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
16. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.
Yadav R; Kakkar A; Sharma A; Malik PS; Sharma MC
Scand J Gastroenterol; 2016 Aug; 51(8):994-9. PubMed ID: 27162024
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
Özaslan E; Demir S; Karaca H; Güven K
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of pancreatic neoplasms and their morphologic correlates: an update on recent advances and potential diagnostic applications.
Reid MD; Saka B; Balci S; Goldblum AS; Adsay NV
Am J Clin Pathol; 2014 Feb; 141(2):168-80. PubMed ID: 24436263
[TBL] [Abstract][Full Text] [Related]
19. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
[TBL] [Abstract][Full Text] [Related]
20. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
